

Prof. Dr. Christoph Rochlitz

Publikationsverzeichnis

(Liste und Impact Factors gemäss:

ISI Web of KnowledgeSM, Journal Citation Reports® vom 16.7.2010)

1: **Rochlitz C**, Hasslacher C, Brocks DG, Herrmann R. Serum concentration of laminin, and course of the disease in patients with various malignancies. **J Clin Oncol.** **1987** Sep;5(9):1424-9. PubMed PMID: 3625257. **IF 17.8**

2: **Rochlitz CF**, Damon LE, Russi MB, Geddes A, Cadman EC. Cytotoxicity of ketoconazole in malignant cell lines. **Cancer Chemother Pharmacol.** **1988**;21(4):319-22. PubMed PMID: 3370740. **IF 2.7**

3: Liu E, Dollbaum C, Scott G, **Rochlitz C**, Benz C, Smith HS. Molecular lesions involved in the progression of a human breast cancer. **Oncogene.** **1988** Sep;3(3):323-7. PubMed PMID: 2849743. **IF 7.1**

4: **Rochlitz CF**, Scott GK, Dodson JM, Benz CC. Use of the polymerase chain reaction technique to create base-specific ras oncogene mutations. **DNA.** **1988** (übergangen in DNA Research) Sep;7(7):515-9. PubMed PMID: 3061761. **IF 4.9**

5: **Rochlitz CF**, Benz CC. Oncogenes in human solid tumors. **Cancer Treat Res.** **1989**;47:199-240. Review. PubMed PMID: 2576998. **IF 8.0**

6: **Rochlitz CF**, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. **Cancer Res.** **1989** Jan 15;49(2):357-60. PubMed PMID: 2642738. **IF 7.5**

7: Damon LE, Christensen S, **Rochlitz C**, Cadman EC. Sequence dependent synergistic cytotoxicity between etoposide and fluoropyrimidines. **Anticancer Res.** **1989** Nov-Dec;9(6):1761-7. PubMed PMID: 2534035. **IF 1.4**

8: Neubauer A, Herbst H, **Rochlitz C**, Siegert W, Schmidt CA, Huhn D. Immunocytochemical detection of p21ras expression in fresh human leukaemic cells and cell lines. **Blut.** **1989** (aufgegangen in Hematology) Nov;59(5):460-3. PubMed PMID: 2684300. **IF 1.3**

9: **Rochlitz CF**, Herrmann R. [Smoking and leukocytosis]. **Dtsch Med Wochenschr.** **1990** May 11;115(19):756. German. PubMed PMID: 2338060. **IF 0.6**

10: **Rochlitz CF**, Peter S, Willroth G, de Kant E, Lobeck H, Huhn D, Herrmann R. Mutations in the ras protooncogenes are rare events in renal cell cancer. **Eur J Cancer.** **1992**;28(2-3):333-6. PubMed PMID: 1591047. **IF 4.1**

11: **Rochlitz CF**, Lobeck H, Peter S, Reuter J, Mohr B, de Kant E, Huhn D, Herrmann R. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. **Cancer.** **1992** Jun 15;69(12):2993-8. PubMed PMID: 1350506. **IF 5.4**

12: Gari-Bai AR, **Rochlitz C**, Riewald M, Oertel J, Huhn D. Treatment of neutropenia in Felty's syndrome with granulocyte-macrophage colony-stimulating factor--hematological response accompanied by pulmonary complications with lethal outcome. **Ann Hematol.** **1992** Nov;65(5):232-5. PubMed PMID: 1457582. **IF 2.9**

13: **Rochlitz CF**, de Kant E, Neubauer A, Heide I, Böhmer R, Oertel J, Huhn D, Herrmann R. PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. **Ann Hematol.** **1992** Dec;65(6):241-6. PubMed PMID: 1360821. **IF 2.9**

14: **Rochlitz CF**, Heide I, de Kant E, Böhmer R, Peter FJ, Neuhaus P, Huhn D, Herrmann R. Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. **Oncology.** **1993**;50(1):70-6. PubMed PMID: 8421601. **IF 2.1**

15: **Rochlitz CF**, Heide I, de Kant E, Neubauer A, Schmidt CA, Neuhaus P, Huhn D, Herrmann R. Molecular alterations in a patient with Turcot's syndrome. **Br J Cancer.** **1993** Sep;68(3):519-23. PubMed PMID: 8394730; PubMed Central PMCID: PMC1968408. **IF 4.3**

16: Neubauer A, de Kant E, **Rochlitz C**, Laser J, Zanetta AM, Gallardo J, Oertel J, Herrmann R, Huhn D. Altered expression of the retinoblastoma susceptibility gene in chronic lymphocytic leukaemia. **Br J Haematol.** **1993** Nov;85(3):498-503. PubMed PMID: 8136272. **IF 4.6**

17: **Rochlitz CF**, Herrmann R. [Hepatocellular carcinoma: systemic chemotherapy, perspectives of gene or immunotherapy]. **Zentralbl Chir.** **1994**;119(11):794-7. Review. German. PubMed PMID: 7846958. **IF 0.5**

- 18: Roth C, **Rochlitz C**, Kourilsky P. Immune response against tumors. **Adv Immunol.** **1994**;57:281-351. Review. PubMed PMID: 7872159. **IF 7.7**
- 19: Schmidt CA, Neubauer A, Seeger KH, **Rochlitz CF**, Binder T, Oettle H, Henze G, Liu ET, Huhn D, Siegert W. Detection of allelic loss within the beta 1-interferon gene in childhood acute lymphoblastic leukemia using differential PCR. **Ann Hematol.** **1994** Apr;68(4):171-4. PubMed PMID: 8003558. **IF 2.9**
- 20: de Kant E, **Rochlitz CF**, Herrmann R. Gene expression analysis by a competitive and differential PCR with antisense competitors. **Biotechniques.** **1994** Nov;17(5):934-42. PubMed PMID: 7840976. **IF 2.5**
- 21: Heide I, Thiede C, Poppe K, de Kant E, Huhn D, **Rochlitz C**. Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. **Br J Cancer.** **1994** Dec;70(6):1267-71. PubMed PMID: 7981087; PubMed Central PMCID: PMC2033689. **IF 4.3**
- 22: Stock KW, Jacob AL, Proske M, Bolliger CT, **Rochlitz C**, Steinbrich W. Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent. **Thorax.** **1995** Nov;50(11):1151-6. PubMed PMID: 8553270; PubMed Central PMCID: PMC475086. **IF 7.0**
- 23: **Rochlitz CF**, Herrmann R. [Adjuvant treatment of colonic carcinoma]. **Praxis.** **1995** Nov 21;84(47):1373-6. German. PubMed PMID: 7501918. **IF nicht gelistet**
- 24: **Rochlitz CF**, Heide I, Thiede C, Herrmann R, de Kant E. Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. **Ann Oncol.** **1995** Dec;6(10):981-6. PubMed PMID: 8750149. **IF 5.6**
- 25: de Kant E, Heide I, Thiede C, Herrmann R, **Rochlitz CF**. MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. **J Cancer Res Clin Oncol.** **1996**;122(11):671-5. PubMed PMID: 8898977. **IF 2.3**
- 26: Merlo A, **Rochlitz C**, Scott R. Survival of patients with Turcot's syndrome and glioblastoma. **N Engl J Med.** **1996** Mar 14;334(11):736-7. PubMed PMID: 8594446. **IF 47.1**
- 27: Garvin AM, Spycher M, Häner M, Torhorst J, Müller H, Herrmann R, **Rochlitz C**, Weber W, Scott RJ. BRCA1 mutations in a selected series of breast/ovarian cancer patients. **J Med Genet.** **1996** Sep;33(9):721-5. PubMed PMID: 8880569; PubMed Central PMCID: PMC1050723. **IF 5.8**

- 28: **Rochlitz CF**, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. **Oncology**. 1996 Nov-Dec;53(6):448-54. PubMed PMID: 8960139. **IF 2.1**
- 29: **Rochlitz CF**, Herrmann R. [Possibilities and prospects in gene therapy in cancer patients]. **Ther Umsch**. 1996 Nov;53(11):847-53. Review. German. PubMed PMID: 8984690. **IF nicht gelistet**
- 30: Lehmann S, **Rochlitz C**. [Hip pain]. **Praxis**. 1997 Feb 11;86(7):261-3. German. PubMed PMID: 9139346. **IF nicht gelistet**
- 31: Heide I, Thiede C, Sonntag T, de Kant E, Neubauer A, Jonas S, Peter FJ, Neuhaus P, Herrmann R, Huhn D, **Rochlitz CF**. The status of p53 in the metastatic progression of colorectal cancer. **Eur J Cancer**. 1997 Jul;33(8):1314-22. PubMed PMID: 9301461. **IF 4.1**
- 32: **Rochlitz CF**, Lohri A, Sasse-Roth G, van Hille B, Reuter J, Tichelli A, Bacchi M, Fopp M, Fey MF, Herrmann R. MTS1 expression and prognosis in acute myeloid leukemia. **Ann Hematol**. 1997 Oct;75(4):141-4. PubMed PMID: 9402846. **IF 2.9**
- 33: Schuler M, **Rochlitz C**, Horowitz JA, Schlegel J, Perruchoud AP, Kommos F, Bolliger CT, Kauczor HU, Dalquen P, Fritz MA, Swanson S, Herrmann R, Huber C. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. **Hum Gene Ther**. 1998 Sep 20;9(14):2075-82. PubMed PMID: 9759934. **IF 4.2**
- 34: Popescu RA, Lohri A, de Kant E, Thiede C, Reuter J, Herrmann R, **Rochlitz CF**. bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. **Eur J Cancer**. 1998 Jul;34(8):1268-73. PubMed PMID: 9849490. **IF 4.1**
- 35: **Rochlitz CF**, Jantscheff P, Bongartz G, Dietrich PY, Quiquerez AL, Schatz C, Mehtali M, Courtney M, Tartour E, Dorval T, Fridman WH, Herrmann R. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors. **Adv Exp Med Biol**. 1998;451:531-7. PubMed PMID: 10026923. **IF 2.0**
- 36: Casella R, **Rochlitz C**, Sauter G, Gasser TC. ["Burned out" testicular tumor: a rare form of germ cell neoplasias]. **Schweiz Med Wochenschr**. 1999 Feb 13;129(6):235-40. German. PubMed PMID: 10093882. **IF 1.7**
- 37: Kauczor HU, Schuler M, Heussel CP, von Weymarn A, Bongartz G, **Rochlitz C**, Huber C, Thelen M. CT-guided intratumoral gene therapy in non-small-cell lung cancer. **Eur Radiol**. 1999;9(2):292-6. PubMed PMID: 10101653. **IF 3.6**

38: **Rochlitz C**, Jantscheff P, Bongartz G, Dietrich PY, Quiquerez AL, Schatz C, Mehtali M, Courtney M, Tartour E, Dorval T, Fridman WH, Herrmann R. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. **Cancer Gene Ther.** 1999 May-Jun;6(3):271-81. PubMed PMID: 10359213. **IF 3.1**

39: Jantscheff P, Herrmann R, **Rochlitz C**. Cancer gene and immunotherapy: recent developments. **Med Oncol.** 1999 Jul;16(2):78-85. Review. PubMed PMID: 10456655. **IF 1.2**

40: Boulay JL, Reuter J, Ritschard R, Terracciano L, Herrmann R, **Rochlitz C**. Gene dosage by quantitative real-time PCR. **Biotechniques.** 1999 Aug;27(2):228-30, 232. PubMed PMID: 10457820. **IF 2.5**

41: Jantscheff P, Herrmann R, Spagnoli G, Reuter J, Mehtali M, Courtney M, **Rochlitz C**. Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells. **Cancer Immunol Immunother.** 1999 Sep;48(6):321-30. PubMed PMID: 10473807. **IF 3.8**

42: **Rochlitz C**, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). **Leukemia.** 1999 Sep;13(9):1352-8. PubMed PMID: 10482985. **IF 8.3**

43: **Rochlitz C**. [Adjuvant systemic therapy of breast cancer--prognostic and predictive factors]. **Swiss Surg.** 1999 (später aufgegangen in Br J Surgery);5(5):222-7. German. PubMed PMID: 10546521. **IF 4.1**

44: Biedermann B, Landmann C, Kann R, Passweg J, Solèr M, Lohri A, **Rochlitz C**, Herrmann R, Pless M. Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer. **Radiother Oncol.** 2000 Aug;56(2):169-73. PubMed PMID: 10927135. **IF 4.3**

45: Donda A, Mori L, Shamshiev A, Carena I, Mottet C, Heim MH, Beglinger C, Grunert F, **Rochlitz C**, Terracciano L, Jantscheff P, De Libero G. Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response. **Eur J Immunol.** 2000 Sep;30(9):2593-603. PubMed PMID: 11009093. **IF 5.2**

46: Boulay JL, Perruchoud AP, Reuter J, Bolliger C, Herrmann R, **Rochlitz C**. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy

in non-small cell lung cancer patients. **Cancer Gene Ther.** 2000 Sep;7(9):1215-9. PubMed PMID: 11023193. **IF 3.1**

47: Tartour E, Mehtali M, Sastre-Garau X, Joyeux I, Mathiot C, Pleau JM, Squiban P, **Rochlitz C**, Courtney M, Jantscheff P, Herrmann R, Pouillart P, Fridman WH, Dorval T. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. **Br J Cancer.** 2000 Dec;83(11):1454-61. PubMed PMID: 11076653; PubMed Central PMCID: PMC2363414. **IF 4.3**

48: Hildebrandt B, Heide I, Thiede C, Nagel S, Dieing A, Jonas S, Neuhaus P, **Rochlitz CF**, Riess H, Neubauer A. Lack of point mutations in exons 11-23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. **Oncology.** 2000 Nov;59(4):344-6. PubMed PMID: 11096348. **IF 2.1**

49: **Rochlitz CF**. Gene therapy of cancer. **Swiss Med Wkly.** 2001 Jan 12;131(1-2):4-9. Review. PubMed PMID: 11205184. **IF 1.7**

50: Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, **Rochlitz C**. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. **J Clin Oncol.** 2001 Mar 15;19(6):1750-8. PubMed PMID: 11251006. **IF 17.8**

51: Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A, Laffer U, Orth B, Metzger U, Stamm B, Martinoli S, Herrmann R, **Rochlitz C**. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. **Genes Chromosomes Cancer.** 2001 Jul;31(3):240-7. PubMed PMID: 11391794. **IF 3.9**

52: Casella R, Moch H, **Rochlitz C**, Meier V, Seifert B, Mihatsch MJ, Gasser TC. Metastatic primitive neuroectodermal tumor of the kidney in adults. **Eur Urol.** 2001 May;39(5):613-7. PubMed PMID: 11464048. **IF 7.7**

53: **Rochlitz C**, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. **Cancer Gene Ther.** 2002 Mar;9(3):289-95. PubMed PMID: 11896446. **IF 3.1**

54: Jantscheff P, Spagnoli G, Zajac P, **Rochlitz CF**. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. **Cancer Immunol Immunother.** 2002 Sep;51(7):367-75. Epub 2002 Jun 25. PubMed PMID:

12192536. **IF 3.8**

55: Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, **Rochlitz C**. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. **Br J Cancer**. 2002 Sep 9;87(6):630-4. Erratum in: *Br J Cancer*. 2003 Jul 21;89(2):422. PubMed PMID: 12237773; PubMed Central PMCID: PMC2364238. **IF 4.3**

56: Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, **Rochlitz C**. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. **Int J Cancer**. 2002 Nov 20;102(3):254-7. PubMed PMID: 12397645. **IF 4.7**

57: Mamot C, Mild G, Reuter J, Laffer U, Metzger U, Terracciano L, Boulay JL, Herrmann R, **Rochlitz C**. Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer. **Br J Cancer**. 2003 Feb 10;88(3):420-3. PubMed PMID: 12569386; PubMed Central PMCID: PMC2747552. **IF 4.3**

58: Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, **Rochlitz C**. SMAD7 is a prognostic marker in patients with colorectal cancer. **Int J Cancer**. 2003 Apr 20;104(4):446-9. PubMed PMID: 12584741. **IF 4.7**

59: **Rochlitz CF**. Gene therapy of cancer. **Drugs Today (Barc)**. 2000 Sep;36(9):619-29. PubMed PMID: 12847567. **IF 1.6**

60: **Rochlitz C**, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. **J Gene Med**. 2003 Aug;5(8):690-9. PubMed PMID: 12898638. **IF 3.0**

61: Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger U, Herrmann R, **Rochlitz C**. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. **J Clin Oncol**. 2003 Oct 1;21(19):3638-46. PubMed PMID: 14512395. **IF 17.8**

62: Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, **Rochlitz C**, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. **Br J Cancer**. 2004 Apr 5;90(7):1312-7. PubMed PMID: 15054447; PubMed Central PMCID: PMC2409680. **IF 4.3**

63: Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A; **Participants***. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. **Breast Cancer Res Treat.** 2004 Jun;85(3):247-54. PubMed PMID: 15111763. **IF 4.7**

64: Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, **Rochlitz C**. Amplification of SKI is a prognostic marker in early colorectal cancer. **Neoplasia.** 2004 May-Jun;6(3):207-12. PubMed PMID: 15153332; PubMed Central PMCID: PMC1502098. **IF 5.0**

65: Niemann B, **Rochlitz C**, Herrmann R, Pless M. Toxic encephalopathy induced by capecitabine. **Oncology.** 2004;66(4):331-5. PubMed PMID: 15218302. **IF 2.1**

66: Battagay M, Berger C, **Rochlitz C**, Hurwitz N, Hirsch HH, De Geyter C, Haque T, Nadal D. Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. **Antivir Ther.** 2004 Jun;9(3):453-9. PubMed PMID: 15259909. **IF 4.3**

67: Uhlmann C, Ballabeni P, Rijken N, Brauchli P, Mingrone W, Rauch D, Pestalozzi BC, **Rochlitz C**, Aebi S; Swiss Group for Clinical Cancer Research; Swiss Institute for Applied Cancer Research. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. **Oncology.** 2004;67(2):117-22. PubMed PMID: 15539915. **IF 2.1**

68: Wenger C, Stern M, Herrmann R, **Rochlitz C**, Pless M. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? **Leuk Lymphoma.** 2005 Jan;46(1):71-5. PubMed PMID: 15621783. **IF 2.4**

69: Stern M, Herrmann R, **Rochlitz C**, Dirnhofer S, Pless M. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma. **Eur J Haematol.** 2005 Mar;74(3):267-70. PubMed PMID: 15693799. **IF 2.3**

70: Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, **Rochlitz C**. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. **Neoplasia.** 2004 Nov-Dec;6(6):813-20. PubMed PMID: 15720808; PubMed Central PMCID: PMC1531685. **IF 5.0**

71: Storojeva I, Boulay JL, Heinimann K, Ballabeni P, Terracciano L, Laffer U, Mild G, Herrmann R, **Rochlitz C**. Prognostic and predictive relevance of

microsatellite instability in colorectal cancer. **Oncol Rep.** 2005 Jul;14(1):241-9. PubMed PMID: 15944796. **IF 1.6**

72: Storojeva I, Boulay JL, Ballabeni P, Buess M, Terracciano L, Laffer U, Mild G, Herrmann R, **Rochlitz C**. Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. **Oncology.** 2005;68(2-3):246-55. Epub 2005 Jul 7. PubMed PMID: 16015041. **IF 2.1**

73: Salzberg M, Thurlimann B, Bonnefois H, Fink D, **Rochlitz C**, von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. **Oncology.** 2005;68(4-6):293-8. Review. PubMed PMID: 16020955. **IF 2.1**

74: Güth U, Singer G, Schötzau A, Langer I, Dieterich H, **Rochlitz C**, Herberich L, Holzgreve W, Wight E. Scope and significance of non-uniform classification practices in breast cancer with non-inflammatory skin involvement: a clinicopathologic study and an international survey. **Ann Oncol.** 2005 Oct;16(10):1618-23. Epub 2005 Jul 20. Review. PubMed PMID: 16033873. **IF 5.6**

75: Guth U, Wight E, Schotzau A, Langer I, Dieterich H, **Rochlitz C**, Herberich L, Holzgreve W, Singer G. Breast carcinoma with noninflammatory skin involvement (T4b): time to abandon an historic relic from the TNM classification. **Cancer.** 2005 Nov 1;104(9):1862-70. PubMed PMID: 16130140. **IF 5.4**

76: Salzberg M, Pless M, **Rochlitz C**, Ambrus K, Scigalla P, Herrmann R. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. **Invest New Drugs.** 2006 Jul;24(4):299-304. PubMed PMID: 16237511. **IF 3.1**

77: Mamot C, **Rochlitz C**. Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology? **Swiss Med Wkly.** 2006 Jan 7;136(1-2):4-12. Review. PubMed PMID: 16597093. **IF 1.7**

78: Güth U, Wight E, Schötzau A, Langer I, Dieterich H, **Rochlitz C**, Herberich L, Holzgreve W, Mihatsch MJ, Singer G. Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). **Hum Pathol.** 2006 Mar;37(3):264-71. PubMed PMID: 16613321. **IF 3.0**

79: Mamot C, Ritschard R, Küng W, Park JW, Herrmann R, **Rochlitz CF**. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. **J Drug Target.** 2006 May;14(4):215-23. PubMed PMID: 16777680. **IF 2.9**

80: Güth U, Wight E, Schötzau A, Langer I, Dieterich H, **Rochlitz C**, Herberich L,

Holzgreve W, Singer G. A new approach in breast cancer with non-inflammatory skin involvement. **Acta Oncol.** **2006**;45(5):576-83. PubMed PMID: 16864172. **IF 2.3**

81: Decker M, Rothermundt C, Holländer G, Tichelli A, **Rochlitz C**. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. **Lancet Oncol.** **2006** Aug;7(8):693-4. Erratum in: *Lancet Oncol.* 2006 Sep;7(9):706. PubMed PMID: 16887487. **IF 14.5**

82: Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, **Rochlitz C**. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. **Eur J Cancer.** **2006** Oct;42(15):2660-1. Epub 2006 Aug 28. PubMed PMID: 16934972. **IF 4.1**

83: Gueth U, Wight E, Schoetzau A, Langer I, Dieterich H, **Rochlitz C**, Herberich L, Holzgreve W, Singer G. Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features. **J Surg Oncol.** **2007** Mar 15;95(4):291-7. PubMed PMID: 17326124. **IF 2.5**

84: Gick U, **Rochlitz C**, Mingrone W, Pestalozzi B, Rauch D, Ballabeni P, Lanz D, Hess V, Aebi S. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. **Oncology.** **2006**;71(1-2):54-60. Epub 2007 Mar 5. PubMed PMID: 17344671. **IF 2.1**

85: Salzberg M, **Rochlitz C**, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schönenberger A, Knuth A, Borner M. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. **Onkologie.** **2007** Jul;30(7):355-60. Epub 2007 Jun 27. PubMed PMID: 17596743. **IF 1.2**

86: Iten F, Müller B, Schindler C, **Rochlitz C**, Oertli D, Mäcke HR, Müller-Brand J, Walter MA. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. **Clin Cancer Res.** **2007** Nov 15;13(22 Pt 1):6696-702. PubMed PMID: 18006770. **IF 6.7**

87: Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A; **Participants***. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. **Breast Cancer Res Treat.** **2009** Jan;113(1):137-44. Epub 2008 Feb 8. PubMed PMID: 18259856; PubMed Central PMCID: PMC2898181. **IF 4.7**

88: Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V,

Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; **Participants***; International Breast Cancer Study Group. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. **Ann Oncol.** 2008 Apr;19(4):660-8. Epub 2008 Feb 13. PubMed PMID: 18272916. **IF 5.6**

89: Regan MM, Pagani O, Walley B, Torrisci R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD; **Participants***; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? **Ann Oncol.** 2008 Jul;19(7):1231-41. Epub 2008 Mar 5. PubMed PMID: 18325918. **IF 5.6**

90: Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Pric, Goldhirsch A, Viale G, Gusterson BA; **Participants***; International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. **Ann Oncol.** 2008 Aug;19(8):1393-401. Epub 2008 Apr 2. PubMed PMID: 18385202; PubMed Central PMCID: PMC2733063. **IF 5.6**

91: Dummer R, **Rochlitz C**, Velu T, Acres B, Limacher JM, Bleuzen P, Lacoste G, Slos P, Romero P, Urosevic M. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. **Mol Ther.** 2008 May;16(5):985-94. Epub 2008 Mar 18. PubMed PMID: 18388930. **IF 6.2**

92: Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, **Rochlitz C**, Rauch D, Schuller JC, Ballabeni P, Ribl K; Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). **Oncology.** 2007;73(3-4):228-37. Epub 2008 Apr 17. PubMed PMID: 18424887. **IF 2.1**

93: Salzberg M, Kirson E, Palti Y, **Rochlitz C**. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. **Onkologie.** 2008 Jul;31(7):362-5. Epub 2008 Jun 24. PubMed PMID: 18596382. **IF 1.2**

94: Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; **Participants***; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. **Breast Cancer Res Treat.** 2009 Aug;116(3):491-500. Epub 2008 Oct 25. PubMed PMID: 18953651. **IF 4.7**

95: Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; **Participants***; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. **J Clin Oncol.** 2008 Dec 1;26(34):5569-75. Epub 2008 Nov 3. PubMed PMID: 18981464; PubMed Central PMCID: PMC2651094. **IF 17.8**

96: Güth U, Huang DJ, Dirnhofer S, **Rochlitz C**, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. **Cancer J.** 2009 Jan-Feb;15(1):81-6. PubMed PMID: 19197181. **IF 3.5**

97: Iten F, Muller B, Schindler C, Rasch H, **Rochlitz C**, Oertli D, Maecke HR, Muller-Brand J, Walter MA. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. **Cancer.** 2009 May 15;115(10):2052-62. PubMed PMID: 19280592. **IF 5.4**

98: Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; **Participants***; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. **Ann Oncol.** 2009 Sep;20(9):1489-98. Epub 2009 May 27. PubMed PMID: 19474112; PubMed Central PMCID: PMC2731016. **IF 5.6**

99: Giobbie-Hurder A, Price KN, Gelber RD; **Participants***; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. **Clin Trials.** 2009 Jun;6(3):272-87. PubMed PMID: 19528136; PubMed Central PMCID: PMC2893024. **IF 1.9**

100: BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS; **Participants***. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. **N Engl J Med.** 2009 Aug 20;361(8):766-76. PubMed PMID: 19692688. **IF 47.1**

101: Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, **Rochlitz C**. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in

early-stage breast cancer. **Neoplasia**. 2009 Oct;11(10):987-1002. PubMed PMID: 19794958; PubMed Central PMCID: PMC2745665. **IF 5.0**

102: Aprili D, Bandschapp O, **Rochlitz C**, Urwyler A, Ruppen W. Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis. **Anesthesiology**. 2009 Dec;111(6):1346-55. Review. PubMed PMID: 19934881. **IF 5.4**

103: Stiefel F, Barth J, Bensing J, Fallowfield L, Jost L, Razavi D, Kiss A; **Participants***. Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009. **Ann Oncol**. 2010 Feb;21(2):204-7. Epub 2009 Dec 21. Review. PubMed PMID: 20026475. **IF 5.6**

104: Rajski M, Zanetti-Dällenbach R, Vogel B, Herrmann R, **Rochlitz C**, Buess M. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. **BMC Med**. 2010 Jan 5;8:1. PubMed PMID: 20051100; PubMed Central PMCID: PMC2823652. **IF 4.0**

105: **Rochlitz C**, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). **Ann Oncol**. 2011 Jan; 22(1): 80-85 [Epub 2010 Jul 1]. **IF 5.6**

106: Vetter M, Tzankov A, Engert A, Mehling M, Herrmann R, **Rochlitz C**. Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature. **Case Rep Oncol**. 2011 Feb 25;4(1):106-14. **IF <1**

107: Schmid SM, Myrick ME, Forrer F, Obermann EC, Viehl CT, **Rochlitz C**, Güth U. Sentinel lymph node biopsy in primary breast cancer: trust the radiolabeled colloid method and avoid unnecessary procedures. **Eur J Surg Oncol**. 2011 Mar;37(3):211-6. **IF 1.4**

108: Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, **Rochlitz C**, Müller-Brand J, Walter MA. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. **J Clin Oncol**. 2011 Jun 10;29(17):2416-23. **IF 17.8**

109: Huober J, Baumann M, **Rochlitz C**, Aebi S, Güth U, von Moos R, Müller A, von Rohr L, Widmer I, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. **Oncology**. 2011 Oct 28;81(3-4):160-166. **IF 2.1**

110: Eichholzer M, Schmid SM, Bovey F, Jordan P, Rohrman S, Huang DJ, **Rochlitz C**, Güth U. Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland. **Arch Gynecol Obstet.** 2011 Aug 4. [Epub ahead of print] **IF 1.0**

111: Wicki A, **Rochlitz C**, Ritschard R, Orleth A, Albrecht I, Herrmann R, Christofori G, Mamot C. Targeting tumor-associated endothelial cells: anti-VEGFR2-immunoliposomes mediate tumor-vessel disruption and inhibit tumor growth. **Clin Cancer Res.** 2011 Nov 7. [Epub ahead of print] **IF 6.7**

Buchkapitel

1. HERRMANN, R., HIDDEMANN, W., NEUBAUER, A., **ROCHLITZ, C.F.**, and HUHN, D. (1989). Therapiestudie zur Behandlung zentrozytisch-zentroblastischer und zentrozytischer Non-Hodgkin-Lymphome mit Interferon. In "**Aktuelle Onkologie**", Vol. 55, pp. 32-35. Zugschwerdt Verlag, München.
2. **ROCHLITZ, C.F.**, PETER, S., WILLROTH, G., and HERRMANN, R. (1990). *Ras* oncogene mutations in renal cell cancer. In "**PCR topics; usage of polymerase chain reaction in genetic and infectious diseases**" (A. Rolfs, H. C. Schumacher, and P. Marx, Eds.), pp. 221-223. Springer Verlag, Berlin, Heidelberg, New York.
3. COHEN, R., CABANIOLS, J.-P., LEVRAUD, J.-P., PANNETIER, C., **ROCHLITZ, C.F.**, ROTH, C., KOURILSKY, P. (1995). Approaches to anti-tumor immunotherapy in mouse and humans. **Genes for development, cell growth and infectious diseases**. Edt. G. Gachelin, Y. Ikawa, S. Ishii, P. Kourilsky, M. Yaniv. John Libbey Eurotext, Paris, 227-236.
4. JANTSCHJEFF, P., DELIBERO, G., BÜRK, M.R., CARENA, I., GRUNERT, F., KAMMERER, R., v. KLEIST, S., HERRMANN, R., **ROCHLITZ, C.F.** (1997). Differential expression of CD66a (biliary glycoprotein) epitopes on activated T-cell subsets. In: **Leukocyte Typing VI**. White Cell Differentiation Antigens, pp. (eds. T. Kishimoto et al.), Garland Publishing, Inc. New York, 115-117.
5. SCHMIDT-WOLF, I., **ROCHLITZ, C.F.** (1999) Genterapie. In: **Kompendium Internistische Onkologie**, 3. Auflage; Hrsg. Schmoll, Höffken, Possinger; Springer Verlag, S. 1304-1310.
6. SCHMIDT-WOLF, I., **ROCHLITZ, C.F.** (1999) Anti-Genterapie. In: **Kompendium Internistische Onkologie**, 3. Auflage; Hrsg. Schmoll, Höffken, Possinger; Springer Verlag S. 1311-1315.
7. **ROCHLITZ, C.F.** (1999). Gene Therapy for Lung Cancer. Contribution to: **Progress in Respiratory Research**, Vol. 30: „Interventional Bronchoscopy“. Editors: C.T. Bolliger, P.N. Mathur, S. 280-289.
8. **ROCHLITZ, C.F.** (1999). Gene Therapy of Cancer with Xenogeneic Cells Expressing Interleukin-2. **BioForum International**, 3, 157-159.
9. **ROCHLITZ, C.F.** (2001) Genterapie, Immuntherapie. Beitrag zu: **Medikamentöse Therapie maligner Erkrankungen**, Urban&Fischer Verlag, Herausgegeben von D. Huhn und R. Herrmann; 4. Auflage, 122-141.
10. **Rochlitz, C.** (2003) Genterapeutische Ansätze bei Krebserkrankungen. In: **Ethik in den Wissenschaften**, Band 7: Ethik und Genterapie; Francke Verlag; Hrsg. Dietmar Mieth, S. 59-69.
11. SCHMIDT-WOLF, I., **ROCHLITZ, C.F.** (2006). Gen- und „Anti“ - Genterapie. In: **Kompendium Internistische Onkologie**, 4. Auflage; Hrsg. Schmoll, Höffken, Possinger; Springer Verlag, S. 837-846.